Global Microfluidic Device Systems Market to Reach $10.7 Billion by 2027
Amid the COVID-19 crisis, the global market for Microfluidic Device Systems estimated at US$3.1 Billion in the year 2020, is projected to reach a revised size of US$10.7 Billion by 2027, growing at a CAGR of 19.6% over the analysis period 2020-2027. In-vitro Diagnostics, one of the segments analyzed in the report, is projected to record a 19.7% CAGR and reach US$6.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Pharmaceuticals segment is readjusted to a revised 17% CAGR for the next 7-year period.
The U.S. Market is Estimated at $914.6 Million, While China is Forecast to Grow at 19.2% CAGR
The Microfluidic Device Systems market in the U.S. is estimated at US$914.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 19.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.7% and 16.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.
Medical Devices Segment to Record 21.6% CAGR
In the global Medical Devices segment, USA, Canada, Japan, China and Europe will drive the 21.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$452.9 Million in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.We bring years of research experience to this 7th edition of our report. The 185-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.Competitors identified in this market include, among others,
- Abbott Laboratories
- Agilent Technologies, Inc.
- Becton, Dickinson & Company
- Bio-Rad Laboratories, Inc.
- Cepheid, Inc.
- Dolomite Microfluidics
- Fluidigm Corporation
- Johnson & Johnson
- Micronit Microtechnologies B.V.
- RainDance Technologies, Inc.
- Roche Diagnostics (Schweiz) AG
- Siemens Healthineers